ABSTRACT
Reducing exposure to cigarette smoke is an imperative for public health, and even more so for diabetic patients. Increasingly, combustion-free technologies for nicotine delivery such as e-cigarettes and heated tobacco products are substituting conventional cigarettes and accelerating the current downward trends in smoking prevalence. However, there is limited information about the long-term health impact in diabetics who use these technologies.
This international randomised controlled trial of type 2 diabetic cigarette smokers will test the hypothesis that following a switch from conventional cigarettes to Combustion-Free Nicotine Delivery Systems (C-F NDS), a measurable improvement in metabolic syndrome (MetS) risk factors and functional parameters will be shown over the course of 2 years.
A total of 576 patients will be randomized (1:2 ratio) to either a control arm (Study Arm A), in which they will be offered referral to smoking cessation programs or to an intervention arm (Study Arm B), in which they will be assigned to C-F NDS use. The primary outcome will be the prevalence of the a difference in MetS score between baseline and 2 years follow-up, with comparison being made between diabetic patients randomized to each arm of the study. Patient recruitment will start in October 2020 and enrolment is expected to be completed by August 2021.
This will be the first study determining the overall health impact of using such technologies in diabetic patients. Data from this study will provide valuable insights into the overall potential of C-F NDS to reduce the risk of cardiovascular disease in individuals, particularly diabetic patients.
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04231838
Competing Interest Statement
Dr. Russo has received honoraria for speaking and financial support to attend meetings/ advisory boards from Novo Nordisk, Sanofi,and Novartis. CR has also served as a consultant for Novo Nordisk and Medtronic. Dr. Belsey reports payments made from Metanoic Health Ltd, for statistical support in the design and conduct of the study; Dr. Polosa is full-time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Novartis, Duska Therapeutics, Alfa-Wassermann, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League) and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4). All other authors have no relevant conflict of interest to declare in relation to this study.
Clinical Trial
NCT04231838
Funding Statement
ECLAT srl, a research spin off company of the University of Catania is the Sponsor of DIASMOKE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRAS project ID:280909 Protocol number: COE1-05-DIASMOKE 2.0 REC reference: 20/LO/0704
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, PS, upon reasonable request.
